Great Eastern reported FY-25 profit attributable to shareholders of SGD 1.21 billion (+21%), with 4Q-25 profit attributable to shareholders at SGD 241.4 million (+79%). FY-25 total weighted new sales fell to SGD 1.54 billion (-15%), while 4Q-25 total weighted new sales rose to SGD 453.7 million (+5%). FY-25 new business embedded value increased to SGD 739.7 million (+19%), and 4Q-25 new business embedded value rose to SGD 241 million (+25%). The board proposed a FY-25 final dividend of SGD 0.30 per share, bringing the FY-25 total dividend to SGD 0.55 per share (+22%), with the final dividend payable on 6 May 2026 subject to shareholder approval. Great Eastern said the FY-25 sales decline reflected a shift away from short-term single-premium products toward longer-term offerings; it also highlighted the launch of 18 new products in Singapore, expansion of its Great Medical Care Concierge proposition, the rollout of AI-enabled advisory and medical claims automation platforms, and the launch of “The Great Journey” integrated healthcare initiative in Malaysia alongside the establishment of Great Eastern Labuan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Great Eastern Holdings Limited published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: CZ8U29FXNHYK9SE7) on February 23, 2026, and is solely responsible for the information contained therein.